Velabs Therapeutics, Heidelberg, Germany, a company specializing in the fast generation of functional therapeutic antibodies, recently announced that it has entered into a collaboration agreement with BioMed X Innovation Center, Heidelberg. The collaboration will capitalize on Velabs’ microfluidics-based technology in the field of T-cell screening.
The BioMed X Innovation Center is a new collaboration model at the interface between academia and industry. BioMed X is using the Velabs platform to support the research team of John Lindner, PhD, which is exploring new concepts for rapid identification of autoantigens in autoimmune diseases. The research team, sponsored by Janssen Research and Development LLC, will use high-throughput microfluidic screening approaches to couple T-cell receptor specificity with autoantigens.
Velabs Therapeutics, a recent startup company of the European Molecular Biology Laboratory (EMBL), is a pioneer in microfluidic technology for functional screening of antibodies and single immune cells. The company’s high-throughput screening platform allows for testing millions of correctly paired fully natural immunoglobulins from humans and mice for therapeutic effects, rather than just for binding. Results are obtained in only a fraction of the time required by other technologies.
The company offers customized screening services for users worldwide. Besides carrying out service projects, Velabs is currently also establishing its own proprietary pipeline of therapeutic antibody candidates for further joint development with pharma partners.
“We are excited by this new cooperation with one of BioMed X’s top research teams,” says Christoph Antz, PhD, managing director of Velabs.
“The company’s capacities in fast screening of single cells and functional antibodies will strongly support a superior performance of BioMed X’s research team,” adds Christoph Merten, PhD, scientific founder and CSO of Velabs.
“In order to address the central challenge of screening and characterizing different immune cells at large scale, the research team chose Velabs’ technology as the most suitable and promising microfluidic screening platform available,” says Christian Tidona, PhD, founder and managing director of BioMed X.
For further information, visit Velabs Therapeutics.